All In Biotech

Drug Trial Radar · NCT00857545

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission

Last checked: Nov 19, 2026Latest source record: Sep 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Jul 2010

Primary completion

Sep 2015

Sponsor

Lead sponsor
Gynecologic Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Mar 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has decreased or disappeared, but the cancer may still be in the body. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether OPT-821 is more effective with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Conditions

  • Stage IA Fallopian Tube Cancer
  • Stage IA Ovarian Cancer
  • Stage IB Fallopian Tube Cancer
  • Stage IB Ovarian Cancer
  • Stage IC Fallopian Tube Cancer
  • Stage IC Ovarian Cancer
  • Stage IIA Fallopian Tube Cancer
  • Stage IIA Ovarian Cancer
  • Stage IIB Fallopian Tube Cancer
  • Stage IIB Ovarian Cancer
  • Stage IIC Fallopian Tube Cancer
  • Stage IIC Ovarian Cancer
  • Stage IIIA Fallopian Tube Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIA Primary Peritoneal Cancer
  • Stage IIIB Fallopian Tube Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIB Primary Peritoneal Cancer
  • Stage IIIC Fallopian Tube Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IIIC Primary Peritoneal Cancer
  • Stage IV Fallopian Tube Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Primary Peritoneal Cancer

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Polyvalent Antigen-KLH Conjugate VaccineBiological

    Given SC

  • Saponin-based Immunoadjuvant OBI-821Biological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Every 3 month until 2 years from start of treatment, then every 6 months for 3 years; then annually if patient remains in remission.

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute

    Palo Alto, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • Beebe Medical Center

    Lewes, Delaware

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois

  • Saint Vincent Oncology Center

    Indianapolis, Indiana

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Union Hospital of Cecil County

    Elkton, Maryland

  • Gynecologic Oncology of West Michigan PLLC

    Grand Rapids, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada

  • Center of Hope at Renown Medical Center

    Reno, Nevada

  • The Women's Institute for Gynecologic Cancer and Special Pelvic Surgery

    Phillipsburg, New Jersey

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico

  • Southwest Gynecologic Oncology Associates Inc

    Albuquerque, New Mexico

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico

  • Winthrop University Hospital

    Mineola, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina

  • Southeast Clinical Oncology Research (SCOR) Consortium NCORP

    Winston-Salem, North Carolina

  • Summa Akron City Hospital/Cooper Cancer Center

    Akron, Ohio

  • University of Cincinnati

    Cincinnati, Ohio

  • Case Western Reserve University

    Cleveland, Ohio

  • Miami Valley Hospital

    Dayton, Ohio

  • Kettering Medical Center

    Kettering, Ohio

  • Lake University Ireland Cancer Center

    Mentor, Ohio

  • University of Toledo

    Toledo, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Abington Memorial Hospital

    Abington, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Women and Infants Hospital

    Providence, Rhode Island

  • AnMed Health Cancer Center

    Anderson, South Carolina

  • Saint Francis Hospital

    Greenville, South Carolina

  • Greenville Health System Cancer Institute-Faris

    Greenville, South Carolina

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.